The easy-to-use1 Trulicity® pen

A way to deliver a GLP-1 RA therapy that was designed with patients in mind2-4

A way to deliver a GLP-1 RA therapy that was designed with patients in mind2-4

Trulicity Pens

Please see Instructions for Use included with the pen.

Easy to use 94%

People with type 2 diabetes, caregivers of people with diabetes, and healthcare professionals who treat diabetes participated in a study on the safe and effective use of the Trulicity pen and the instructions for the Trulicity pen. One hundred and twenty-eight people completed a questionnaire on their experience using the pen and the instructions. The questionnaire contained multiple questions regarding ease of use of the pen including, "overall easy to use the medication delivery device."1

Easy to use 94%

People with type 2 diabetes, caregivers of people with diabetes, and healthcare professionals who treat diabetes participated in a study on the safe and effective use of the Trulicity pen and the instructions for the Trulicity pen. One hundred and twenty-eight people completed a questionnaire on their experience using the pen and the instructions. The questionnaire contained multiple questions regarding ease of use of the pen including, "overall easy to use the medication delivery device."1

References

  1. Data on file, Lilly USA, LLC. TRU20140910L.
  2. Trulicity [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC; 2015.
  3. Trulicity [Instructions for Use]. Indianapolis, IN: Lilly USA, LLC; 2014.
  4. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287-296.
  5. Data on file, Lilly USA, LLC. TRU20140918A.